Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:50:58 EST Wed 17 Dec 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Z:IGC - IGC PHARMA INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IGC - Z2.00.324·0.36790.10.336+0.00511.5760.32328510.334  0.3443  0.32070.4985  0.252519:51:02Dec 1515 min RT 2¢

Recent Trades - Last 10 of 851
Time ETExPriceChangeVolume
19:51:02Z0.33890.00492
19:42:48Z0.3390.00516
19:37:56Z0.3390.00510
19:32:48Z0.3390.0051
19:31:16Z0.33890.0049144
19:28:54Z0.33660.00262
19:23:44Z0.3390.005115
19:22:10Z0.3390.005340
19:19:33Z0.33890.00491
19:17:03Z0.3390.0055,300

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-15 09:00U:IGCNews ReleaseIGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines
2025-12-10 09:00U:IGCNews ReleaseIGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."
2025-12-09 09:00U:IGCNews ReleaseIGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
2025-12-02 09:00U:IGCNews ReleaseIGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease
2025-11-25 09:00U:IGCNews ReleaseIGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends
2025-11-17 08:30U:IGCNews ReleaseIGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital
2025-11-13 09:00U:IGCNews ReleaseUSPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders
2025-11-10 09:00U:IGCNews ReleaseIGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025
2025-11-03 08:53U:IGCNews ReleaseIGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline
2025-10-22 09:00U:IGCNews ReleaseIGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"
2025-10-14 09:00U:IGCNews ReleaseIGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences
2025-10-10 19:51U:IGCNews ReleaseIGC Pharma Announces Results of 2025 Annual Meeting of Stockholders
2025-10-07 09:00U:IGCNews ReleaseIGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease
2025-09-29 09:00U:IGCNews ReleaseIGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial
2025-09-24 09:00U:IGCNews ReleaseIGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology
2025-09-22 09:00U:IGCNews ReleaseIGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
2025-09-09 09:17U:IGCNews ReleaseIGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection
2025-09-02 09:00U:IGCNews ReleaseIGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada
2025-08-28 09:00U:IGCNews ReleaseIGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome
2025-08-27 09:00U:IGCNews ReleaseIGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50."